

# World Journal of *Gastroenterology*

*World J Gastroenterol* 2017 June 21; 23(23): 4135-4316





### EDITORIAL

- 4135 Attenuated adenomatous polyposis of the large bowel: Present and future  
*Roncucci L, Pedroni M, Mariani F*
- 4140 Evolution of associating liver partition and portal vein ligation for staged hepatectomy: Simpler, safer and equally effective methods  
*Peng SY, Wang XA, Huang CY, Zhang YY, Li JT, Hong DF, Cai XJ*

### REVIEW

- 4146 Antioxidant dietary approach in treatment of fatty liver: New insights and updates  
*Ferramosca A, Di Giacomo M, Zara V*
- 4158 *Helicobacter pylori* BabA in adaptation for gastric colonization  
*Ansari S, Yamaoka Y*

### MINIREVIEWS

- 4170 Advances in surgical management for locally recurrent rectal cancer: How far have we come?  
*Lee DJK, Sagar PM, Sadacharam G, Tan KY*

### ORIGINAL ARTICLE

#### Basic Study

- 4181 Anti-steatotic and anti-fibrotic effects of the KCa3.1 channel inhibitor, Senicapoc, in non-alcoholic liver disease  
*Paka L, Smith DE, Jung D, McCormack S, Zhou P, Duan B, Li JS, Shi J, Hao YJ, Jiang K, Yamin M, Goldberg ID, Narayan P*
- 4191 Induction of chronic cholestasis without liver cirrhosis - Creation of an animal model  
*Dondorf F, Fahrner R, Ardelt M, Patsenker E, Stickel F, Dahmen U, Settmacher U, Rauchfuß F*
- 4200 Solid lipid nanoparticles delivering anti-inflammatory drugs to treat inflammatory bowel disease: Effects in an *in vivo* model  
*Dianzani C, Foglietta F, Ferrara B, Rosa AC, Muntoni E, Gasco P, Della Pepa C, Canaparo R, Serpe L*
- 4211 Relevance of proteolysis and proteasome activation in fatty liver graft preservation: An Institut Georges Lopez-1 vs University of Wisconsin appraisal  
*Zaouali MA, Panisello-Roselló A, Lopez A, Castro Benítez C, Folch-Puy E, García-Gil A, Carbonell T, Adam R, Roselló-Catafau J*

- 4222** Naturally occurring mutations in the reverse transcriptase region of hepatitis B virus polymerase from treatment-naïve Korean patients infected with genotype C2

*Kim JE, Lee SY, Kim H, Kim KJ, Choe WH, Kim BJ*

- 4233** Inhibition of N-methyl-N-nitrosourea-induced gastric tumorigenesis by Liuwei Dihuang Pill in db/db mice

*Zhuang S, Jian YM, Sun YN*

- 4243** miR-382 functions as a tumor suppressor against esophageal squamous cell carcinoma

*Feng J, Qi B, Guo L, Chen LY, Wei XF, Liu YZ, Zhao BS*

**Case Control Study**

- 4252** Pancreas preserving distal duodenectomy: A versatile operation for a range of infra-papillary pathologies

*Mitchell WK, Thomas PF, Zaitoun AM, Brooks AJ, Lobo DN*

**Retrospective Study**

- 4262** Clinical importance of colonoscopy in patients with gastric neoplasm undergoing endoscopic submucosal dissection

*Tsuchida C, Yoshitake N, Kino H, Kaneko Y, Nakano M, Tsuchida K, Tominaga K, Sasai T, Masuyama H, Yamagishi H, Imai Y, Hiraishi H*

- 4270** Outcomes of right-lobe and left-lobe living-donor liver transplantations using small-for-size grafts

*She WH, Chok KSH, Fung JYY, Chan ACY, Lo CM*

**Clinical Trials Study**

- 4278** Potential application of neogalactosylalbumin in positron emission tomography evaluation of liver function

*Du SD, Li SH, Jin B, Zhu ZH, Dang YH, Xing HQ, Li F, Wang XB, Lu X, Sang XT, Yang HY, Zhong SX, Mao YL*

**Observational Study**

- 4285** Magnetic resonance imaging may predict deep remission in patients with perianal fistulizing Crohn's disease

*Thomassin L, Armengol-Debeir L, Charpentier C, Bridoux V, Koning E, Savoye G, Savoye-Collet C*

- 4293** New totally intracorporeal reconstructive approach after robotic total gastrectomy: Technical details and short-term outcomes

*Parisi A, Ricci F, Gemini A, Trastulli S, Cirocchi R, Palazzini G, D'Andrea V, Desiderio J*

**EVIDENCE-BASED MEDICINE**

- 4303** Substantial hepatic necrosis is prognostic in fulminant liver failure

*Ndekwe P, Ghabril MS, Zang Y, Mann SA, Cummings OW, Lin J*

**CASE REPORT**

- 4311** Benefit of everolimus in treatment of an intrahepatic cholangiocarcinoma patient with a *PIK3CA* mutation

*Bian JL, Wang MM, Tong EJ, Sun J, Li M, Miao ZB, Li YL, Zhu BH, Xu JJ*

**ABOUT COVER**

Editorial board member of *World Journal of Gastroenterology*, Akira Hokama, MD, PhD, Professor, Department of Endoscopy, University of the Ryukyus, Nishihara, Okinawa 903-0215, Japan

**AIMS AND SCOPE**

*World Journal of Gastroenterology* (*World J Gastroenterol*, *WJG*, print ISSN 1007-9327, online ISSN 2219-2840, DOI: 10.3748) is a peer-reviewed open access journal. *WJG* was established on October 1, 1995. It is published weekly on the 7<sup>th</sup>, 14<sup>th</sup>, 21<sup>st</sup>, and 28<sup>th</sup> each month. The *WJG* Editorial Board consists of 1375 experts in gastroenterology and hepatology from 68 countries.

The primary task of *WJG* is to rapidly publish high-quality original articles, reviews, and commentaries in the fields of gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, hepatobiliary surgery, gastrointestinal oncology, gastrointestinal radiation oncology, gastrointestinal imaging, gastrointestinal interventional therapy, gastrointestinal infectious diseases, gastrointestinal pharmacology, gastrointestinal pathophysiology, gastrointestinal pathology, evidence-based medicine in gastroenterology, pancreatology, gastrointestinal laboratory medicine, gastrointestinal molecular biology, gastrointestinal immunology, gastrointestinal microbiology, gastrointestinal genetics, gastrointestinal translational medicine, gastrointestinal diagnostics, and gastrointestinal therapeutics. *WJG* is dedicated to become an influential and prestigious journal in gastroenterology and hepatology, to promote the development of above disciplines, and to improve the diagnostic and therapeutic skill and expertise of clinicians.

**INDEXING/ABSTRACTING**

*World Journal of Gastroenterology* (*WJG*) is now indexed in Current Contents<sup>®</sup>/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch<sup>®</sup>), Journal Citation Reports<sup>®</sup>, Index Medicus, MEDLINE, PubMed, PubMed Central and Directory of Open Access Journals. The 2017 edition of Journal Citation Reports<sup>®</sup> released by Clarivate Analytics (Former Thomson Reuters) cites the 2016 impact factor for *WJG* as 3.365 (5-year impact factor: 3.176), ranking *WJG* as 29<sup>th</sup> among 79 journals in gastroenterology and hepatology (quartile in category Q2).

**FLYLEAF**

**I-IX** Editorial Board

**EDITORS FOR THIS ISSUE**

**Responsible Assistant Editor:** *Xiang Li*  
**Responsible Electronic Editor:** *Fen-Fen Zhang*  
**Proofing Editor-in-Chief:** *Lian-Sheng Ma*

**Responsible Science Editor:** *Ze-Mao Gong*  
**Proofing Editorial Office Director:** *Jin-Lei Wang*

**NAME OF JOURNAL**  
*World Journal of Gastroenterology*

**ISSN**  
 ISSN 1007-9327 (print)  
 ISSN 2219-2840 (online)

**LAUNCH DATE**  
 October 1, 1995

**FREQUENCY**  
 Weekly

**EDITORS-IN-CHIEF**  
**Damian Garcia-Olmo, MD, PhD, Doctor, Professor, Surgeon**, Department of Surgery, Universidad Autonoma de Madrid; Department of General Surgery, Fundacion Jimenez Diaz University Hospital, Madrid 28040, Spain

**Stephen C Strom, PhD, Professor**, Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Stockholm 141-86, Sweden

**Andrzej S Tarnawski, MD, PhD, DSc (Med), Professor of Medicine, Chief Gastroenterology**, VA Long Beach Health Care System, University of California, Irvine, CA, 5901 E. Seventh Str., Long Beach,

CA 90822, United States

**EDITORIAL BOARD MEMBERS**  
 All editorial board members resources online at <http://www.wjgnet.com/1007-9327/editorialboard.htm>

**EDITORIAL OFFICE**  
 Jin-Lei Wang, Director  
 Yuan Qi, Vice Director  
 Ze-Mao Gong, Vice Director  
*World Journal of Gastroenterology*  
 Baishideng Publishing Group Inc  
 7901 Stoneridge Drive, Suite 501,  
 Pleasanton, CA 94588, USA  
 Telephone: +1-925-2238242  
 Fax: +1-925-2238243  
 E-mail: [editorialoffice@wjgnet.com](mailto:editorialoffice@wjgnet.com)  
 Help Desk: <http://www.fpublishing.com/helpdesk>  
<http://www.wjgnet.com>

**PUBLISHER**  
 Baishideng Publishing Group Inc  
 7901 Stoneridge Drive, Suite 501,  
 Pleasanton, CA 94588, USA  
 Telephone: +1-925-2238242  
 Fax: +1-925-2238243  
 E-mail: [bpoffice@wjgnet.com](mailto:bpoffice@wjgnet.com)  
 Help Desk: <http://www.fpublishing.com/helpdesk>

<http://www.wjgnet.com>

**PUBLICATION DATE**  
 June 21, 2017

**COPYRIGHT**  
 © 2017 Baishideng Publishing Group Inc. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

**SPECIAL STATEMENT**  
 All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

**INSTRUCTIONS TO AUTHORS**  
 Full instructions are available online at <http://www.wjgnet.com/bpg/gerinfo/204>

**ONLINE SUBMISSION**  
<http://www.fpublishing.com>

## ***Helicobacter pylori* BabA in adaptation for gastric colonization**

Shamshul Ansari, Yoshio Yamaoka

Shamshul Ansari, Yoshio Yamaoka, Department of Environmental and Preventive Medicine, Oita University Faculty of Medicine, Yufu-City, Oita 879-5593, Japan

Yoshio Yamaoka, Department of Medicine-Gastroenterology, Baylor College of Medicine, Houston, TX 77030, United States

**Author contributions:** Yamaoka Y conceived the design of the manuscript; Ansari S searched the published articles, extracted the core information and prepared the initial draft of the manuscript; Yamaoka Y revised the draft of the manuscript.

**Supported by** (in part) grants from the National Institutes of Health, No. DK62813; the Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology (MEXT) of Japan, No. 25293104, No. 26640114, No. 15H02657 and No. 16H05191 to Yamaoka Y; Japan Society for the Promotion of Science Institutional Program for Young Researcher Overseas Visits to Yamaoka Y; the Strategic Funds for the Promotion of Science and Technology from Japan Science and Technology Agency to Yamaoka Y; and the Japanese Government (Monbukagakusho: MEXT) Scholarship Program to Ansari S.

**Conflict-of-interest statement:** The authors declare that they have no any conflict of interests.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Correspondence to:** Yoshio Yamaoka MD, PhD, Department of Environmental and Preventive Medicine, Oita University Faculty of Medicine, 1-1 Idaigaoka, Hasama-machi, Yufu-City, Oita 879-5593, Japan. [yyamaoka@oita-u.ac.jp](mailto:yyamaoka@oita-u.ac.jp)  
Telephone: +81-97-5865740

Fax: +81-97-5865749

Received: January 28, 2017

Peer-review started: February 7, 2017

First decision: March 16, 2017

Revised: April 12, 2017

Accepted: June 1, 2017

Article in press: June 1, 2017

Published online: June 21, 2017

### **Abstract**

*Helicobacter pylori* (*H. pylori*) as a causative agent of gastric complications, is well adapted for the colonization of gastric mucosa. Although the infectious process depends on several factors, the adhesion to the gastric mucosa is the first and important step. Among several outer membrane proteins, BabA is one of the significant protein involving in many inflammatory processes in addition to its role in the attachment for the persistent colonization. We performed a PubMed search using the key words: "babA", "pylori", "gastric complications", "homologous recombination", "slipped strand mispairing"; a total of 249 articles were displayed. Of these we mainly focused on articles with the full text in English and published between 2005 and 2016. *H. pylori* BabA is involved in binding with receptors; however, its synthesis is regulated by phase variation. In this review we confirm that *H. pylori* babA can be modulated at the molecular and functional levels to adapt to the stress within the gastro-intestinal tract.

**Key words:** BabA; Gastric complications; *Helicobacter pylori*; Homologous recombination; Slipped strand mispairing

© **The Author(s) 2017.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** *Helicobacter pylori* are well adapted to colonize the gastric mucosa. Although the infectious process depends on several factors, adhesion to the gastric mucosa is the first and critical step. Among outer membrane proteins, BabA is an important protein involved in many inflammatory processes in addition to playing a role in the aforementioned attachment process. In this review, we have summarized the current, published knowledge regarding its functional and molecular aspects by which the pathogen can attach to the host cell receptors.

Ansari S, Yamaoka Y. *Helicobacter pylori* BabA in adaptation for gastric colonization. *World J Gastroenterol* 2017; 23(23): 4158-4169 Available from: URL: <http://www.wjgnet.com/1007-9327/full/v23/i23/4158.htm> DOI: <http://dx.doi.org/10.3748/wjg.v23.i23.4158>

## INTRODUCTION

The *Helicobacter pylori* (*H. pylori*) is a helical, Gram-negative bacterium that chronically infects the stomach of half of the world's population<sup>[1]</sup>. Since this bacterium is strongly associated with the development of duodenal ulcer and gastric cancer, International Agency for Research on Cancer categorized this bacterium under strong carcinogen (group I carcinogen) in 1994<sup>[2,3]</sup>. The global burden of gastric cancer is high which accounts for 6.2% of cancer burden worldwide<sup>[4]</sup>. However, the appearance of new cases of gastric cancer has been found variable in developing (8.4%) and developed countries (4.5%)<sup>[5]</sup>. Mortality rate due to the gastric cancer is the third most common cause among all cancer related deaths<sup>[6,7]</sup>.

Although the exact means of transmission of this bacterium is not understood clearly the evidences suggest that this bacterium is transmitted from person to person contact between family members *via* fecal-oral or oral-oral route and mostly the infections are acquired in childhood<sup>[8-10]</sup>. The data from epidemiological studies conducted support the transmission of infection by exposure to contaminated water or food as well<sup>[11,12]</sup>. The socio-economic status of family highly reflects the infection rate among peoples as the infection rate tends to be higher in peoples belonging to family with low socio-economic status<sup>[13]</sup>. This contribution highly suggests the higher prevalence rate of *H. pylori* infection in developing countries than the developed countries. The infection rate ranging from 70%-90% and 25%-50% in developing and developed countries respectively<sup>[14]</sup>.

*H. pylori* related clinical outcomes also depend on the ancestral relation between human and bacterium as suggested recently. The individuals infected with non-ancestral strains that are not evolutionarily adapted to their host develop severe histo-pathological

damage and clinical outcomes than infected with co-evolutionarily developed strains<sup>[15]</sup>. However, being a truly opportunistic pathogen, the *H. pylori* utilizes the various virulence factors such as CagA and VacA as the effector protein for the development of gastric diseases<sup>[16]</sup> and the outer membrane proteins (OMPs) such as blood group antigen binding adhesion (BabA), sialic acid binding adhesin (SabA), and outer inflammatory protein (OipA) found on the surface (adhesins) of bacterial cell envelop for the attachment to the mucus layer of the gastric epithelium playing an important and initial step for the colonization and development of persistent infection for decades or for entire life time<sup>[17-19]</sup>.

## LITERATURE SEARCH

We conducted a PubMed search using the key terms "babA", "pylori", "gastric complications", "homologous recombination", "slipped strand mispairing"; 249 articles were found during the search. We focused on, but did not limit ourselves to, articles with the full text in English and published between 2005 and December 2016. For greater clarity and insight we considered few articles published between 1989 and 2005. We retrieved a total of 98 articles that studied BabA and its paralogs, presence, function, production, and role in the development of gastric complications, attachment to host cells, and adaptation. Abstract only publications, case reports, editorials, and review articles were excluded. While performing the search, irrelevant articles with authors' family names as 'Baba' were also excluded. We also performed a literature search in Google using the terms: "pylori", "gastric cancer", and "slipped strand mispairing". Through this, we selected three reports that were not indexed in PubMed.

### ***bab* paralogous genes and their chromosomal location**

*H. pylori* colonization elicits humoral and cellular immune responses although, ineffective in the bacterial clearance. However, despite of the peristaltic movement of the intestinal tract and movement of the chyme, the bacterium establishes the strong interaction with the epithelial surfaces. The bacterial attachment on the epithelial surface is the interaction between the receptor molecules on the host cell surface and adhesin molecules found on the bacterial cell envelope and this interaction is the first and important step of the *H. pylori* related pathogenicity. The Gram-negative bacterial cell envelope consists of two concentric lipid bilayers, the inner membrane (cytoplasmic membrane) and the outer membrane. More than 50% of the outer membrane mass consists of OMPs. *H. pylori* genome encodes a large number of OMPs and most of them are surface exposed and consists of transport channels (porins), and adhesins. The closely related (at least partially redundant)

**Table 1 Chromosomal location of *babA*, *babB* and *babC* genes in different strains**

Strain	Locus A	Locus B	Locus C
26695	<i>babB</i>	<i>babA</i>	<i>babC</i>
J99	<i>babA</i>	<i>babB</i>	No corresponding gene
HPAG1	<i>babA</i>	<i>babC</i>	<i>babB</i>
G27	<i>babC</i>	No corresponding gene	<i>babA</i>
51	<i>babA</i>	<i>babB</i>	No corresponding gene
Shi470	<i>babA</i>	<i>babB</i>	No corresponding gene
P12	<i>babA</i>	<i>babB</i>	<i>babB</i> homolog <sup>1</sup>
52	<i>babA</i>	<i>babB</i>	No corresponding gene
B38	<i>babA</i>	No corresponding gene	No corresponding gene
v225d	<i>babA</i>	<i>babB</i>	No corresponding gene
SJM180	<i>babB</i>	<i>babC</i>	<i>babA</i>
PeCan4	<i>babA</i>	<i>babB</i>	No corresponding gene
Sat464	<i>babA</i>	<i>babB</i>	No corresponding gene
35A	<i>babA</i>	<i>babB</i>	No corresponding gene
India7	<i>babA</i>	<i>babB</i>	No corresponding gene
Gambia94/24	<i>babA</i>	<i>babB</i>	No corresponding gene
SouthAfrica7	<i>babA</i>	<i>babA</i>	No corresponding gene
Ok1112	<i>babA</i>	<i>babA</i>	No corresponding gene
Ok1154	<i>babA</i>	<i>babB</i>	No corresponding gene
Ok1828	<i>babA</i>	<i>babA</i>	No corresponding gene
J166	<i>babA</i>	<i>babB</i>	No corresponding gene
SNT49	<i>babA</i>	<i>babB</i>	No corresponding gene
Puno120	<i>babA</i>	<i>babB</i>	No corresponding gene
Puno135	<i>babA</i>	<i>babB</i>	No corresponding gene
B8	<i>babA</i>	<i>babA</i>	No corresponding gene
83	<i>babA</i>	<i>babB</i>	No corresponding gene
ELS37	<i>babB</i>	<i>babA</i>	No corresponding gene
HUP-B14	<i>babA</i>	<i>babC</i>	No corresponding gene
F16	<i>babA</i>	<i>babB</i>	No corresponding gene
F30	<i>babA</i>	<i>babB</i>	No corresponding gene
Hp238	<i>babA</i>	<i>babB</i>	No corresponding gene
BM013A	<i>babB</i>	<i>babB</i>	No corresponding gene
29CaP	<i>babA</i>	<i>babA</i>	No corresponding gene

<sup>1</sup>Although the gene is homologous to *babB* but due to the insertion of adenine (A) caused the formation of stop codon and premature termination.

proteins are grouped into paralogous families<sup>[20]</sup>.

Among the large group of adhesins identified BabA, SabA, adherence associated lipoprotein A and B (AlpA/B), OipA, and HopZ<sup>[17,18,21-24]</sup>, BabA (or HopS or OMP28) is around 75-80 kDa major OMP which was the first identified member of adhesin family<sup>[25]</sup>. Two other closely related paralogs to BabA has been found, the BabB (HopT or OMP19) and BabC (HopU or OMP9)<sup>[26]</sup>. The function of BabB and BabC is not known yet and needs to be determined. The *bab* gene sequence analysis revealed that there is extensive 5' and 3' region homology particularly between *babA* and *babB* but the variability in middle region of sequence suggests that the middle divergent region of *babA* likely mediates the binding function<sup>[26,27]</sup>.

The *babA*, *babB* and *babC* genes can be located in at least 3 different chromosomal loci. The three marker genes *hypD*, *s18* and heme oxygenase gene *hp0318* represent the chromosomal location of *bab* genes. The *bab* gene found downstream of *hypD*,

*s18* and *hp0318* is said to be located at locus A, locus B and locus C respectively<sup>[28]</sup>. For example; in strain J99 (where *babC* is absent), *babA* (*jhp0833*) and *babB* (*jhp1164*) are located downstream of *hypD* and *s18* (locus A and locus B) respectively whereas in strain 26695, the locations for *babA* and *babB* are reversed; *babA* (*hp1243*), *babB* (*hp0896*) and *babC* (*hp0317*) are located downstream of *s18*, *hypD* and *hp0318* (locus B, locus A and locus C) respectively. Similarly, in strain HPAG1, the *babA*, *babB* and *babC* are located downstream of *hypD*, *hp0318* and *s18* (locus A, locus C and locus B) respectively whereas in strain G27 (where *babB* is absent), *babA* and *babC* are located downstream of *hp0318* and *hypD* (locus C and locus A) respectively and in strain 51 (where *babC* is absent), the *babA* and *babB* are located downstream of *hypD* and *s18* (locus A and locus B) respectively<sup>[29-31]</sup> as shown in Table 1. We made an attempt to find the *bab* genes in respective to their genomic locus in different strains deposited in gene bank. Among *H. pylori* deposited in gene bank by 30 November 2016, we randomly selected the 33 strains for the characterization of chromosomal locations of *bab* genes (*babA*, *babB* and *babC*) (Table 1). Although, the chromosomal locations of *babA*, *babB* and *babC* in few strains such as J99, 26695, HPAG1, G27 and 51 already have been described yet in other strains we made an effort to document the chromosomal location of these genes. In strain P12 there is a *babB* homologous gene at locus C but due to the insertion of one adenine (A) at position 679 resulted the shift in the nucleotide frame and the stop codon at position 230 and premature termination of the amino acid sequence. The reports of several studies from various parts of the world depicts that in majority of the strains *babA* and *babB* prefers to be located at locus A and locus B respectively<sup>[28-30,32]</sup>. Despite of the three identified loci there can be an unidentified locus. In a study, Hennig *et al.*<sup>[29]</sup> found *babA* sequences from 2 strains not located at locus A, B or C and they hypothesized that there may be a yet not identified chromosomal locus for *babA*.

### Production of BabA

As discussed in previous section, the *babA* can be located in at least three different identified loci. The BabA production has been claimed to be influenced by its genomic location. In strain J99, *babA* located at locus A is expressed and binds with Lewis blood group (Leb) antigen whereas in strain 26695; *babA* located at locus B is not expressed and does not bind to Leb antigen<sup>[33,34]</sup>. The detailed mechanisms involved in the expression of *babA* have not been depicted in detail. However, we have summarized the possible mechanisms published in several literatures.

The strain CCUG17875 was reported to possess two alleles of *babA* denoted as *babA1* found at locus B and *babA2* found at locus A<sup>[34]</sup>. The allelic form *babA1*

does not contain the translation initiation codon ATG because of the deletion of 10 bp including start codon in its signal sequence and is not expressed whereas the *babA2* containing the translation initiation codon ATG is expressed and involved in the Leb binding activity<sup>[34]</sup>. The expression of *babA* can be influenced on transcriptional as well as translational level. The absence of translation initiation codon ATG in *babA1* influence the translation, but this phenomenon is quite uncommon. Nonetheless, unfortunately, several epidemiological studies still use the methods to characterize *babA2* as the functional status of *babA* by using primers specific for the signal region to differentiate *babA1* and *babA2*. The presence of variable number of cytosine-thiamidine (CT) dinucleotide in the 5'-region of the *babA* sequence due to the intra-genomic recombination with *babB* leads to the phase variation and affects the expression of *babA* (discussed in latter section). The characteristics of the promoter sequence also play a critical role in the expression of *babA*. During protein expression all mRNAs are not synthesized in the same amount because of the promoter characteristics which controls the expression on transcriptional level. In a study, the presence of additional 4 adenines between the -10 and -35 motif in *babA* located at locus B could diminished the strength of the promoter of *babA*<sup>[34]</sup>. The nucleotide structure of -10 and -35 motifs sequence and the characteristics of nucleotides present between the -10 and -35 motifs tend to make the promoter strong or weak. For example, the promoter region of one of the OMP gene *sabA* contains a thymidine (T) nucleotide repeat tract adjacent to the -35 motif and the length of this T-tract varies between strain to strain and this variation have been suggested to affect the expression of *sabA*<sup>[35-37]</sup>. Recently it has been also suggested that the T-tract modulates the binding of RNA polymerase  $\sigma$ -factor and  $\alpha$ -factor resulting in the alteration of SabA expression<sup>[38]</sup>. The nucleotide repeat motifs located between the -35 and -10 promoter motifs influence the docking of RNA polymerase  $\sigma$ -factor and the nucleotide repeat motif located upstream of -35 motif alters the binding of regulatory factors of RNA polymerase<sup>[38]</sup>. However, the detailed studies are needed to evaluate the characteristics of promoter regions responsible for the variation in expression of *babA* in loci A/B/C.

*H. pylori babA* is highly polymorphic being susceptible for the changes in their regulatory and coding sequence that leads to the loss of BabA expression in multiple animal models including mice, gerbils and macaques; therefore, it is difficult to study the role of BabA contribution in the development of gastric damages<sup>[39]</sup>. However, it has been shown that in *H. pylori* isolated from the chronically infected persons, the BabA expression was maintained in three quarter of the isolates surveyed over time and it suggests that there is selective advantage for BabA expression in human host<sup>[40]</sup>.

### Occurrences of *babA* containing *H. pylori*

Most epidemiological studies have reported the *babA* functional status using the *babA2* specific primers designed to detect the 10-bp deletion in the signal region of the *babA1* allele and its association with increased risk for gastric inflammation<sup>[41]</sup>. The reported prevalence of *H. pylori* containing *babA* shows great variation across different parts of the world<sup>[28,32,42-55]</sup> as shown in Table 2. However, we previously reported the BabA expression level by immunoblotting and Leb binding in diverse collection of *H. pylori* strains and divided in to high, low, and non BabA expressing strains<sup>[52]</sup>. The strains expressing low level of BabA were associated with higher incidence of gastrointestinal damages as compared to BabA with high expression and BabA negative strains. It was concluded that although, the *babA2* detection provides an indication of functional *babA* status, it may not reliably reflect the complete information of genetic variants for *babA* expression.

### BabA and its binding receptors

Adherence of *H. pylori* to the host cell receptor provides several benefits to the bacteria such as protection from the washing out during mucus shedding, provides nutrient access from damaged host epithelial cells, promotes delivery of the bacterial toxins and other effector molecules to the host cells for development of pathogenicity and facilitates the development of persistent infections<sup>[56-58]</sup>. The attachment of bacteria to the host cells also elicits immune response; however, no longer protective in *H. pylori* infection. Several functional molecules serving as a receptor for the binding of *H. pylori* through BabA has been reported (Table 3).

Since the postulated transmission for the *H. pylori* infection takes place through oral route, the possible initial attachment could be occurred with the salivary proteins. The BabA mediates the attachment by binding with difucosylated glycans found on Leb antigens of the salivary mucin MUC5B serving as a receptor for BabA<sup>[59,60]</sup>. The surface immobilized salivary agglutinin; glycoproteins-340 (gp-340) also provides the platform for the attachment of BabA<sup>[61]</sup>. Salivary prolin rich glycoprotein (PRG) is the major component of parotid and submandibular saliva containing several repeats of short prolin rich sequence. Salivary PRG containing Fuc $\alpha$ 1-2Gal $\beta$  motif also provides the access for the attachment of BabA<sup>[59]</sup>. The secretory immunoglobulin A (s-IgA) is the major immunoglobulin found in the mucus secretions which protects the mucus membrane from invading organisms. However, the fucose-containing oligosaccharide motifs on s-IgA could play a role in the binding phenomena of BabA<sup>[17]</sup>. However, in a study this phenomenon was not confirmed suggesting that the variation in the glycosylation and sialylation between the salivary and gastric s-IgA or the proportions of s-IgA1 and s-IgA2 subclasses

**Table 2** Prevalence of *babA* in different Asian and other countries

Ref.	Countries	Criteria for <i>babA</i> positive	Prevalence	Year
	Asia			
Abdullah <i>et al</i> <sup>[43]</sup>	Iraq	Positive with <i>babA2</i> specific primers	33.7% in NUD and 58.8% in PUD	2012
Karabiber <i>et al</i> <sup>[44]</sup>	Turkey	Positive with <i>babA2</i> specific primers	49% in gastritis	2014
Abadi <i>et al</i> <sup>[45]</sup>	Iran	Positive with <i>babA2</i> specific primers	Overall-40.6%	2013
			95%-GC, 18.1-DU, 26.1-NUD	
Yadegar <i>et al</i> <sup>[46]</sup>	Iran	Positive with <i>babA2</i> specific primers	Overall-96.7%	2014
			94.4%-NUD, 100%-PUD, 100%-GE, 100%-GC	
Saberi <i>et al</i> <sup>[42]</sup>	Iran	BabA expression	Overall-62%	2016
Osman <i>et al</i> <sup>[47]</sup>	Malaysia	Positive with <i>babA2</i> specific primers	41%-NUD	2015
Boonyanugomol <i>et al</i> <sup>[48]</sup>	Thailand	Positive with <i>babA2</i> specific primers	Overall-66.2%,	2012
			70.7%-CCA, 54.5%-Cholelithiasis	
Chomvarin <i>et al</i> <sup>[49]</sup>	Thailand	Positive with <i>babA2</i> specific primers	Overall-92%	2008
			92%-NUD, 85%-GU, 100%-DU, 94%-GC	
Ghosh <i>et al</i> <sup>[50]</sup>	India	Positive with <i>babA2</i> specific primers	Overall-67.5%	2016
			65.6%-NUD, 70%-DU	
Con <i>et al</i> <sup>[51]</sup>	Japan	Positive with <i>babA2</i> specific primers	Overall-96.8%	2010
Fujimoto <i>et al</i> <sup>[52]</sup>	Japan	Leb binding activity	Over all-88.0%	2007
Kim <i>et al</i> <sup>[32]</sup>	South Korea	Positive with <i>babA</i> specific primers	Overall-47.5%	2015
	Other countries			
Kim <i>et al</i> <sup>[32]</sup>	United States	Positive with <i>babA</i> specific primers	Overall-90%	2015
Biernat <i>et al</i> <sup>[53]</sup>	Poland	Positive with <i>babA2</i> specific primers	Overall-23.1%	2014
			18%-NUD, 30%-PUD, 31.8%-GERD	
Homan <i>et al</i> <sup>[54]</sup>	Slovenia	Positive with <i>babA2</i> specific primers	Overall-47.9%	2014
Boyanova <i>et al</i> <sup>[55]</sup>	Bulgaria	Positive with <i>babA2</i> specific primers	Overall-48.8%	2010
			59.3%-PUD, 43.5%-NUD	
Matteo <i>et al</i> <sup>[28]</sup>	Argentina	Positive with <i>babA</i> specific primers	Overall-67%	2011
Con <i>et al</i> <sup>[51]</sup>	Costa-Rica	Positive with <i>babA2</i> specific primers	Overall-73.7%	2010
Fujimoto <i>et al</i> <sup>[52]</sup>	Colombia	Leb binding activity	Overall-83.0%	2007

NUD: Non-ulcer disease; PUD: Peptic ulcer disease; GC: Gastric cancer; DU: Duodenal ulcer; GE: Gastric erosion; CCA: Cholangiocarcinoma; GERD: Gastroesophageal reflux disease; GU: Gastric ulcer.

**Table 3** BabA receptors found on oral cavity and in stomach

Receptors identified	Localization	Ref.
Mucin MUC5B	Saliva	Walz <i>et al</i> <sup>[59]</sup> and Prakobphol <i>et al</i> <sup>[60]</sup>
Agglutinin glycoprotein-340 (gp-340)	Saliva	Prakobphol <i>et al</i> <sup>[61]</sup>
Prolin rich glycoprotein containing Fucc1-2Galβ motif	Saliva	Walz <i>et al</i> <sup>[59]</sup>
Secretory immunoglobulin A containing fucose-oligosaccharide motifs	Saliva	Borén <i>et al</i> <sup>[17]</sup> and Royle <i>et al</i> <sup>[62]</sup>
Salivary agglutinin DMBT1	Saliva	Issa <i>et al</i> <sup>[63]</sup>
Lewis b blood group antigen (Leb) and terminal fucose, H1-antigen, A-antigen and B-antigen	Gastric epithelia	Borén <i>et al</i> <sup>[17]</sup> and McGuckin <i>et al</i> <sup>[64]</sup>
Mucin MUC5AC with N-acetylgalactosamine-β-1,4-N-acetylglucosamine	Gastric mucus	Lindén <i>et al</i> <sup>[68]</sup> and Kenny <i>et al</i> <sup>[69]</sup>
Mucin MUC1	Gastric mucus	Lindén <i>et al</i> <sup>[71]</sup>
Mucin MUC2	Gastric mucus	Cohen <i>et al</i> <sup>[72]</sup>

which are known to be differently glycosylated may play this role<sup>[62]</sup>. Similarly, a salivary agglutinin called the deleted in malignant brain tumors 1 (DMBT1) is expressed in saliva and composed of highly fucosylated oligosaccharide. The salivary DMBT1 was found to act as the receptor to interact with BabA<sup>[63]</sup>.

After transit to the stomach, the bacterium localizes to the specific locations and mediates adaptation through several ways. The gastrointestinal epithelium is covered by a semi-permeable mucus layer primarily consists of secreted mucins that protects the gastric epithelial surface by trapping the invading materials<sup>[64]</sup>. However, the attachment of bacteria to the epithelial

surface mediates the survival adaptation and persistent infections. The di-fucosylated glycan found on Leb and mono-fucosylated glycans found on H1-antigen, A-antigen and B-antigen of blood group O, A and B respectively binds with BabA<sup>[17,33,65]</sup>. However, the binding affinity of BabA with H1 antigen is low because it lacks the Leb Fuc4 residue that forms a hydrogen bond with amino acid asparagine (N) at 206 position of BabA<sup>[66]</sup> as described below in next section. These antigens are expressed on the mucus surface and gastric epithelial surface of which the Leb antigen is the dominant antigen found on the surface of gastric epithelial cells and it is also the most studied receptor

**Table 4** Oligosaccharides found in Leb involving in binding with amino acid of BabA

Oligosaccharide in Leb	Amino acid in BabA	Position of amino acid in BabA
Fuc1	Cysteine (C)	189
Fuc1	Glycine (G)	191
Fuc1	Asparagine (N)	194
Fuc4	Asparagine (N)	206
GlcNAc3 or Gal5	Aspartic acid (D)	233
Gal5	Serine (S)	234
GlcNAc3 or Gal5	Serine (S)	244
Fuc1	Threonine (T)	246

for BabA attachment<sup>[67]</sup>.

Similarly, other molecules have also been reported to play a crucial role in the binding of BabA. The gastric mucin MUC5AC with N-acetylgalactosamine- $\beta$ -1,4-N-acetylglucosamine residues on O-linked oligosaccharides from gastric MUC5AC has also been reported to act as receptor for BabA<sup>[68,69]</sup>. Most recent immunohistochemistry laden tissue profiling assay using mice model showed that the expression of Leb structure is a mucin  $\alpha$  1,2-fucosyltransferase (FUT2) enzyme dependent and consequently identified MUC5AC as the carrier molecule of the Leb structure<sup>[70]</sup>.

The MUC1 is also notable to discuss. In case when bacteria do not bind to MUC1, an extracellular mucin domain of 200-500 nm long appears that physically distances the bacteria from the host cell surface and in case when it does bind MUC1, the extracellular mucin domain is released from the epithelial surface<sup>[71]</sup>. In another study by Cohen *et al.*<sup>[72]</sup> conducted in children, the gastric mucin MUC2 was reported to be expressed in few foveolar cells and it was shown to participate in binding with BabA but only in 11.11% of children. Therefore, fucosylated glycans found on several glycoprotein molecules serve as the receptor.


### Insight into BabA binding with receptors

The detailed molecular determination of BabA binding with its receptor Leb was studied recently by Hage *et al.*<sup>[66]</sup>. They depicted that the Leb oligosaccharide molecules involving in the binding with BabA consists of two fucose residues (Fuc1 and Fuc4), two galactose residues (Gal2 and Gal5), an N-acetylglucosamine residue (GlcNAc3), and a glucose residue (Glc6). Using strain J99 as an experimental model they found that 8 highly conserved amino-acids of BabA involved in the interaction with Leb by hydrogen bond formation. The bond formation occurs between amino acid cysteine (C) at position 189 and Fuc1 (C189:Fuc1), glycine (G) at position 191 and Fuc1 (G191:Fuc1), asparagine (N) at position 194 and Fuc1 (N194:Fuc1), asparagine (N) at position 206 and Fuc4 (N206:Fuc4), aspartic acid (D) at position 233 and GlcNAc3 (D233:GlcNAc3), aspartic acid (D) at position 233 and Gal5 (D233:Gal5), serine (S) at position 234 and Gal5 (S234:Gal5), serine (S) at position 244 and GlcNAc3 (S244:

GlcNAc3, Gal5), serine (S) at position 244 and Gal5 (S244:Gal5) and threonine (T) at position 246 and Fuc1 (T246:Fuc1) (Table 4). They also elaborated that the binding of N at position 206 with Fuc4 determines the binding affinity and substitution of N with alanine (A) at position 206 resulted in the reduction of binding affinity by about 2.3-fold and the binding of BabA with H-1 which lacks Fuc4 residue of Leb showed about 2.4 fold reduction in binding affinity<sup>[66]</sup>. Despite of the role of Leb for providing the binding receptor and enhancing the colonization, the several reports indicate the antagonistic effect of Leb. In a study led by Lindén *et al.*<sup>[73]</sup> found that the individuals with Leb-negative showed significantly higher *H. pylori* density than Leb-positive, which is in accordance with the result obtained in a study using Rhesus monkey<sup>[74]</sup>. Therefore, it can be said that although, the attachment of bacterium *via* BabA-Leb is important but not elusive.

Based on their ABO blood group antigen binding preferences, BabA bearing *H. pylori* strains can be classified as "specialists" and "generalists". The specialist strains prefer to bind only on blood group O specific glycans whereas generalist strains bind blood group O as well as blood group A and B specific glycans<sup>[65]</sup>. Till recently the detailed insight concept about the binding of specialists and generalists with the mono-fucosylated glycan on A, B and O blood group was unknown. However, recently the X-ray structures of the BabA specialist and generalist adhesins have been revealed according to the O and ABO blood group preferences<sup>[75]</sup>. The preference shifting was found to be due to the single amino acid substitution in its carbohydrate binding domain. The carbohydrate binding domain contains one conserved loop (CL2) and two diversity loop (DL1 and DL2). The loop DL1 is responsible for making the BabA to be either specialist or generalist. Binding of specialists with blood group O antigen involves only CL2 and DL2 loops while the binding of generalists involve CL2, DL2 as well as DL1 loops. In specialists BabA, the domain DL1 contains the amino acid leucine (L) at 198 position which makes the DL1 to be inaccessible for binding with larger glycans present on blood group A and B. The replacement of L to serine (S) in generalists makes the DL1 to be accessible for the glycans found on blood group A and B as well as O (Figure 1). In this way the generalists can bind with glycans found on blood group A, B as well as O antigen whereas the specialists can bind the glycan found on blood group O antigen only<sup>[75]</sup>. Therefore, this capability of binding explains why the peoples of blood group O are more prone to develop duodenal ulcers<sup>[65]</sup>. The fucosylated oligosaccharide residue found on the H1 antigen is abundantly expressed by the healthy gastric mucosa of most Western peoples which makes them more susceptible to colonize by generalists as well as specialists and for the development of peptic ulcer<sup>[17,76]</sup>.

The binding of BabA to the Leb receptor is severely affected by the level of BabA production which is



**Figure 1** In BabA generalists the serine (S) at position 198 makes the DL1 domain to be accessible for the glycan found on blood group A, B as well as O antigen whereas in BabA specialists the replacement of S to leucine (L) makes DL1 to be inaccessible for binding with larger glycans present on blood group A and B antigen.

mediated on transcriptional and translational level. We detected that the strains expressing low levels (less than 10% to that of J99) of BabA protein did not mediate the enough Leb binding activity whereas, the strains expressing high level (more than 20% to that of J99) of BabA did enough Leb binding<sup>[52]</sup>. However, Saberi *et al.*<sup>[42]</sup> categorized the *H. pylori* strains in four types depending on the BabA expression and Leb-binding, strains expressing high level BabA showed high Leb-binding, strains expressing low level BabA showed low Leb-binding whereas strains with no BabA expression showed no Leb-binding (8%) as well as low Leb-binding (30%) activity.

**Homologous recombination and bab chimera formation**  
Recombination between similar sequences is called the homologous recombination. Homologous recombination takes part in the double strand DNA repair caused by environmental stress and it aids adaptation advantage for the development of persistent colonization to *H. pylori* to the changing gastric environment within a single host or to the new host<sup>[77-79]</sup>. *H. pylori* exhibits the highest genetic recombination rate than any other known bacterial species<sup>[80]</sup> and it suggests that the bacteria has a selective advantage of genetic recombination for long term survival and colonization in human stomach<sup>[81]</sup>.


The allelic diversity in *H. pylori* is remarkable and it exhibits high transformation mediated homologous recombination<sup>[77]</sup>. Recent analyses of sequential sampling of *H. pylori* from the same individual elaborated the OMPs *futB*, *babA* and *hopZ* to be the genes with high recombination events whereas the *hopQ* with low recombination<sup>[82,83]</sup>. Although the function of the most closely related *babA* paralogs; the *babB* and *babC*, is unknown yet but extensive sequence similarity shows the intra-genomic recombination between these genes and the evolution of *bab* chimera<sup>[35]</sup>. The RecA-dependent intragenomic recombination between homologous genes causing fusion of portions of two or more coding regions results in the formation of chimeric genes. In *H. pylori* the

recombinational gene conversion occurs in homologous genes *babA*, *babB* and *babC*. The formation of chimeric *babB/A* can lead to a non Leb binding strains regain Leb binding activity or it can abolish *babA*-dependent adhesion<sup>[35,84]</sup>. Varying proportions of chimeras have been reported from different studies across the world. In a study by Matteo *et al.*<sup>[28]</sup>, the chimeric *babA/B* gene was observed in 20% whereas chimeric *babB/A* gene was observed in 15%. Similarly, in another study among American and Korean strains, the *babA/B* chimera, *babB/A* chimera and *babB/C* chimera was identified in 28.7%, 2.5% and 1.25% respectively among American strains whereas *babA/B* chimera and *babB/A* chimera was identified from 6.25% and 1.25% respectively from Korean strains. The *babA/B* was most prevalent type of *bab* chimera among all types of chimera reported<sup>[32]</sup>.

**Slipped strand mispairing and phase variation**

Slipped strand mispairing (SSM) is a phenomenon of either deletion or insertion of nucleotides during DNA replication because of the short, contiguous homogenous or heterogeneous repetitive DNA sequence of 6 base pairs or less. This repetitive sequence, susceptible for mispairing is designated as short sequence repeats (SSR), microsatellites or variable number of tandem repeats (VNTR)<sup>[85,86]</sup>. SSM is one of the mechanisms resulting in the phase variation that produces nucleotide mispairing between the mother and daughter strand during the DNA replication<sup>[87,88]</sup>. The OMP genes such as *babB*, *hopZ*, *oipA* that possess the dinucleotide CT-repeats in the 5'-coding region, likely undergo SSM to regulate their expression by phase variation<sup>[18,89,90]</sup>. Nucleotide slippage can be occurred in replicating or template strand. If slippage occurs in replicating strand, there is insertion of one CT-dinucleotide and if slippage occurs in template strand, there is deletion of one CT-dinucleotide (Figure 2)<sup>[91]</sup>. This phenomenon leading to the variation in the number of CT-dinucleotides over time may provide certain advantages for adaptation to different niches and stomach micro-environments *via* immune evasion or adhesion. In *H. pylori*, the fragments of *babB* containing CT repeats may recombine with *babA* or *babC* resulting in the formation of chimeric genes. According to the Bäckström *et al.*<sup>[34]</sup> the strains with in-frame protein expression (ON) status contain 8-CT repeats whereas out of frame protein expression (OFF) phenotypes contained 7 or 9 CT repeats. The gain or loss of one CT-dinucleotide creates frame shifts and loss of expression of *babA*.

The number of CT-repeats in the 5'coding region of nucleotide sequence decides whether the protein expression is ON or OFF. The protein expression becomes in-frame if the number of CT-repeats is 5, 8, 11 and 14 whereas if the number of CT-repeats is 6, 7, 9, 10, 12, 13 it makes protein expression out of frame<sup>[30,34,84]</sup>. Out of frame status of protein



**Figure 2 Cytosine-thiamidine-dinucleotide repeats and slipped strand mis-pairing.** Both replicating and template strands are prone to undergo for slippage mis-pairing. Slippage occurring in replicating strand during first generation of replication causes insertion of one CT-dinucleotide in replicating strand whereas the template strand contains original number of CT-dinucleotide. If slippage occurs in template strand during first generation replication, one CT-dinucleotide is deleted in replicating strand to make base pairing. During second generation of DNA replication, out of two progeny generating from slippage in replicating strand, one progeny contains DNA with one CT-dinucleotide more than the mother strain while the other progeny contains same number of CT-dinucleotide as mother strain. During second generation of DNA replication, out of two progeny generating from slippage in template strand, one progeny contains DNA with one CT-dinucleotide less than the mother strain while other progeny contains DNA with same number of CT-dinucleotide as do mother strain. CT: Cytosine-thiamidine.

expression evolved due to the insertion or deletion of one nucleotide resulting in the truncated (immature) proteins whereas if the status is in-frame it results in the full-length protein expression<sup>[92]</sup>.

The genes containing variable number of nucleotide repeats may go to the phase variation. Phase variation is an adaptation mechanism that provides advantages for colonization<sup>[93]</sup>. In a study, the BabA expression was lost during the experimental infection in rhesus macaques by phase variation or allele replacement with BabB and in subsequent follow up study in mouse, the BabA expression was found to be lost due to phase variation in 5'-CT repeat regions of *H. pylori* strain J166<sup>[39]</sup>. The Leb binding clones from OFF to ON phase conversion express BabA adhesin that are functionally equivalent to the wild type but the quantity of BabA adhesin less abundant than the wild type<sup>[34]</sup>.

**Other clinical significance of BabA mediated attachment**

The attachment of *H. pylori* via BabA mediates several outcomes. *H. pylori* BabA binds with Leb and induces the double strand breaks in the host cells, which is thought to be independent of VacA,  $\gamma$ -glutamyl transpeptidase and the *cag* PAI<sup>[94]</sup>. However, it has been also confirmed that BabA-positive status of infecting strains is associated with CagA-positive, OipA-positive (*oipA* "on") and *vacA* s1 genotype for the development of intestinal metaplasia<sup>[95]</sup>. The infection with BabA-positive strains has been associated with

the increased risk for development of peptic ulcer diseases in Western countries<sup>[41,96]</sup>. However, the association of BabA with peptic ulcer diseases has not been confirmed in patients from East Asian or some other Western countries<sup>[97-99]</sup>. It has been claimed that the BabA-mediated attachment to gastric epithelial cells might enhance CagA translocation and the enhancement of inflammation<sup>[100]</sup>. Furthermore, the triple-positive (BabA, CagA and *vacA* s1-positive) strains of *H. pylori* shows greater colonization densities, elevated levels of gastric inflammation and a higher incidence of intestinal metaplasia in patients in contrast with the only CagA and *vacA*s1 positive strains<sup>[101,41]</sup>. Despite of the association of high level BabA with severe clinical outcomes, surprisingly, it has been also found that low level BabA expressing strains could more likely be associated with increased mucosal inflammation and severe clinical outcomes compared to that of high level BabA-positive and Leb binding strains<sup>[42,52]</sup>. Although, the underlying mechanisms remains unclear, it has been hypothesized that during adulthood, the induced hyperacidity may enhance the development of gastric metaplastic patches in the duodenum and the *H. pylori* expressing low levels of BabA and Leb attachment are able to detach from the gastric niche and reattached to the gastric metaplastic patches in the duodenum and develop the ulcers at the gastric-duodenal tissue border<sup>[42]</sup>. The BabA adhesin expression also seems tightly associated

with the onset of type 4 secretory system (T4SS)-related host response *in vivo*<sup>[100]</sup>. In an *in vivo* study, using the Mongolian gerbils, the BabA-mediated adherence of *H. pylori* to the epithelial cells has been shown to augment the *cag* PAI dependent *H. pylori* pathogenicity. The BabA-Leb interaction can trigger the production of pro-inflammatory cytokines and some factors that can enhance the cancer development<sup>[101]</sup>.

## CONCLUSION

*H. pylori* infection is a major cause of gastric complications including gastric cancer which is the third leading cause for mortality among all cancer related deaths. *H. pylori* being a Gram-negative organism, the OMP present in the cell envelope provides the initial step binding with the Leb antigen for the persistent colonization. BabA is capable of binding with receptors found on the oral mucosa and gastric mucus layer. The closer insight of *bab* genes revealed the presence of dinucleotide (CT) repeats in 5'-region which causes SSM leading to the phase variation. The formation of chimera with the homologous genes *babB* and *babC* causes the regulation of protein expression on transcriptional level. In addition to the high level BabA expression associated with the severe clinical outcomes many reports have also suggested the low level expression with severe outcomes where the underlying mechanism is not clear yet. Even though many roles of BabA in disease process have been evaluated, the role of BabB and BabC has not been assessed yet. Further study is under demand for the assessment of the role of BabB and BabC as well as to elaborate the underlying mechanism of low expression BabA and severe clinical outcomes.

## REFERENCES

- 1 **Kusters JG**, van Vliet AH, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. *Clin Microbiol Rev* 2006; **19**: 449-490 [PMID: 16847081 DOI: 10.1128/CMR.00054-05]
- 2 Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June 1994. *IARC Monogr Eval Carcinog Risks Hum* 1994; **61**: 1-241 [PMID: 7715068]
- 3 **IARC Helicobacter pylori Working Group**. Helicobacter pylori Eradication as a Strategy for Preventing Gastric Cancer. Lyon, France 2014: International Agency for Research on Cancer (IARC Working Group Reports, No. 8). Available from: URL: <http://www.iarc.fr/en/publications/pdfsonline/wrk/wrk8/index.php>
- 4 **Plummer M**, Franceschi S, Vignat J, Forman D, de Martel C. Global burden of gastric cancer attributable to Helicobacter pylori. *Int J Cancer* 2015; **136**: 487-490 [PMID: 24889903 DOI: 10.1002/ijc.28999]
- 5 **Ferlay J**, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer* 2015; **136**: E359-E386 [PMID: 25220842 DOI: 10.1002/ijc.29210]
- 6 GLOBOCON 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. Available from: URL: [http://globocan.iarc.fr/Pages/fact\\_sheets\\_cancer.aspx](http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx)
- 7 **Wroblewski LE**, Peek RM, Wilson KT. Helicobacter pylori and

- gastric cancer: factors that modulate disease risk. *Clin Microbiol Rev* 2010; **23**: 713-739 [PMID: 20930071 DOI: 10.1128/CMR.00011-10]
- 8 **Mamishi S**, Eshaghi H, Mahmoudi S, Bahador A, Hosseinpour Sadeghi R, Najafi M, Farahmand F, Khodadad A, Pourakbari B. Intrafamilial transmission of Helicobacter pylori: genotyping of faecal samples. *Br J Biomed Sci* 2016; **73**: 38-43 [PMID: 27182676 DOI: 10.1080/09674845.2016.1150666]
- 9 **Goh KL**, Chan WK, Shiota S, Yamaoka Y. Epidemiology of Helicobacter pylori infection and public health implications. *Helicobacter* 2011; **16** Suppl 1: 1-9 [PMID: 21896079 DOI: 10.1111/j.1523-5378.2011.00874.x]
- 10 **Bui D**, Brown HE, Harris RB, Oren E. Serologic Evidence for Fecal-Oral Transmission of Helicobacter pylori. *Am J Trop Med Hyg* 2016; **94**: 82-88 [PMID: 26598563 DOI: 10.4269/ajtmh.15-0297]
- 11 **Ranjbar R**, Khamesipour F, Jonaidi-Jafari N, Rahimi E. Helicobacter pylori isolated from Iranian drinking water: vacA, cagA, iceA, oipA and babA2 genotype status and antimicrobial resistance properties. *FEBS Open Bio* 2016; **6**: 433-441 [PMID: 27419049 DOI: 10.1002/2211-5463.12054]
- 12 **Talaei R**, Souod N, Momtaz H, Dabiri H. Milk of livestock as a possible transmission route of Helicobacter pylori infection. *Gastroenterol Hepatol Bed Bench* 2015; **8**: S30-S36 [PMID: 26171135]
- 13 **Graham DY**, Malaty HM, Evans DG, Evans DJ, Klein PD, Adam E. Epidemiology of Helicobacter pylori in an asymptomatic population in the United States. Effect of age, race, and socioeconomic status. *Gastroenterology* 1991; **100**: 1495-1501 [PMID: 2019355]
- 14 **Rowland M**, Daly L, Vaughan M, Higgins A, Bourke B, Drumm B. Age-specific incidence of Helicobacter pylori. *Gastroenterology* 2006; **130**: 65-72; quiz 211 [PMID: 16401469 DOI: 10.1016/S0016-5107(99)70352-4]
- 15 **Kodaman N**, Pazos A, Schneider BG, Piazuelo MB, Mera R, Sobota RS, Sicinski LA, Shaffer CL, Romero-Gallo J, de Sablet T, Harder RH, Bravo LE, Peek RM, Wilson KT, Cover TL, Williams SM, Correa P. Human and Helicobacter pylori coevolution shapes the risk of gastric disease. *Proc Natl Acad Sci USA* 2014; **111**: 1455-1460 [PMID: 24474772 DOI: 10.1073/pnas.1318093111]
- 16 **Yamaoka Y**. Mechanisms of disease: Helicobacter pylori virulence factors. *Nat Rev Gastroenterol Hepatol* 2010; **7**: 629-641 [PMID: 20938460 DOI: 10.1038/nrgastro.2010.154]
- 17 **Borén T**, Falk P, Roth KA, Larson G, Normark S. Attachment of Helicobacter pylori to human gastric epithelium mediated by blood group antigens. *Science* 1993; **262**: 1892-1895 [PMID: 8018146 DOI: 10.1126/science.8018146]
- 18 **Mahdavi J**, Sondén B, Hurtig M, Olfat FO, Forsberg L, Roche N, Angstrom J, Larsson T, Teneberg S, Karlsson KA, Altraja S, Wadström T, Kersulyte D, Berg DE, Dubois A, Petersson C, Magnusson KE, Norberg T, Lindh F, Lundskog BB, Arnqvist A, Hammarström L, Borén T. Helicobacter pylori SabA adhesin in persistent infection and chronic inflammation. *Science* 2002; **297**: 573-578 [PMID: 12142529 DOI: 10.1126/science.1069076]
- 19 **Yamaoka Y**, Kwon DH, Graham DY. A M(r) 34,000 proinflammatory outer membrane protein (oipA) of Helicobacter pylori. *Proc Natl Acad Sci USA* 2000; **97**: 7533-7538 [PMID: 10852959 DOI: 10.1073/pnas.130079797]
- 20 **Alm RA**, Bina J, Andrews BM, Doig P, Hancock RE, Trust TJ. Comparative genomics of Helicobacter pylori: analysis of the outer membrane protein families. *Infect Immun* 2000; **68**: 4155-4168 [PMID: 10858232 DOI: 10.1128/IAI.68.7.4155-4168.2000]
- 21 **Yamaoka Y**. Roles of Helicobacter pylori BabA in gastroduodenal pathogenesis. *World J Gastroenterol* 2008; **14**: 4265-4272 [PMID: 18666312 DOI: 10.3748/wjg.14.4265]
- 22 **Moore ME**, Borén T, Solnick JV. Life at the margins: modulation of attachment proteins in Helicobacter pylori. *Gut Microbes* 2011; **2**: 42-46 [PMID: 21637017 DOI: 10.4161/gmic.2.1.14626]
- 23 **Odenbreit S**, Till M, Hofreuter D, Faller G, Haas R. Genetic and functional characterization of the alpAB gene locus essential for

- the adhesion of *Helicobacter pylori* to human gastric tissue. *Mol Microbiol* 1999; **31**: 1537-1548 [PMID: 10200971 DOI: 10.1046/j.1365-2958.1999.01300.x]
- 24 **Peck B**, Ortkamp M, Diehl KD, Hundt E, Knapp B. Conservation, localization and expression of HopZ, a protein involved in adhesion of *Helicobacter pylori*. *Nucleic Acids Res* 1999; **27**: 3325-3333 [PMID: 10454640]
- 25 **Iiver D**, Arnqvist A, Ogren J, Frick IM, Kersulyte D, Incecik ET, Berg DE, Covacci A, Engstrand L, Borén T. *Helicobacter pylori* adhesin binding fucosylated histo-blood group antigens revealed by retagging. *Science* 1998; **279**: 373-377 [PMID: 9430586 DOI: 10.1126/science.279.5349.373]
- 26 **Pride DT**, Blaser MJ. Concerted evolution between duplicated genetic elements in *Helicobacter pylori*. *J Mol Biol* 2002; **316**: 629-642 [PMID: 11866522 DOI: 10.1006/jmbi.2001.5311]
- 27 **Pride DT**, Meinersmann RJ, Blaser MJ. Allelic Variation within *Helicobacter pylori* babA and babB. *Infect Immun* 2001; **69**: 1160-1171 [PMID: 11160014 DOI: 10.1128/IAI.69.2.1160-1171.2001]
- 28 **Matteo MJ**, Armitano RI, Romeo M, Wonaga A, Olmos M, Catalano M. *Helicobacter pylori* bab genes during chronic colonization. *Int J Mol Epidemiol Genet* 2011; **2**: 286-291 [PMID: 21915366]
- 29 **Hennig EE**, Allen JM, Cover TL. Multiple chromosomal loci for the babA gene in *Helicobacter pylori*. *Infect Immun* 2006; **74**: 3046-3051 [PMID: 16622249 DOI: 10.1128/IAI.74.5.3046-3051.2006]
- 30 **Colbeck JC**, Hansen LM, Fong JM, Solnick JV. Genotypic profile of the outer membrane proteins BabA and BabB in clinical isolates of *Helicobacter pylori*. *Infect Immun* 2006; **74**: 4375-4378 [PMID: 16790815 DOI: 10.1128/IAI.00485-06]
- 31 National Center for Biotechnology Information (NCBI): *Helicobacter pylori*. Available from: URL: <https://www.ncbi.nlm.nih.gov/genome/genomes/169>
- 32 **Kim A**, Servetas SL, Kang J, Kim J, Jang S, Cha HJ, Lee WJ, Kim J, Romero-Gallo J, Peek RM, Merrell DS, Cha JH. *Helicobacter pylori* bab Paralogs Distribution and Association with cagA, vacA, and homA/B Genotypes in American and South Korean Clinical Isolates. *PLoS One* 2015; **10**: e0137078 [PMID: 26317221 DOI: 10.1371/journal.pone.0137078]
- 33 **Hennig EE**, Mernaugh R, Edl J, Cao P, Cover TL. Heterogeneity among *Helicobacter pylori* strains in expression of the outer membrane protein BabA. *Infect Immun* 2004; **72**: 3429-3435 [PMID: 15155649 DOI: 10.1128/IAI.72.6.3429-3435.2004]
- 34 **Bäckström A**, Lundberg C, Kersulyte D, Berg DE, Borén T, Arnqvist A. Metastability of *Helicobacter pylori* bab adhesin genes and dynamics in Lewis b antigen binding. *Proc Natl Acad Sci USA* 2004; **101**: 16923-16928 [PMID: 15557006 DOI: 10.1073/pnas.0404817101]
- 35 **Goodwin AC**, Weinberger DM, Ford CB, Nelson JC, Snider JD, Hall JD, Paules CI, Peek RM, Forsyth MH. Expression of the *Helicobacter pylori* adhesin SabA is controlled via phase variation and the ArsRS signal transduction system. *Microbiology* 2008; **154**: 2231-2240 [PMID: 18667556 DOI: 10.1099/mic.0.2007/016055-0]
- 36 **Kao CY**, Sheu SM, Sheu BS, Wu JJ. Length of thymidine homopolymeric repeats modulates promoter activity of sabA in *Helicobacter pylori*. *Helicobacter* 2012; **17**: 203-209 [PMID: 22515358 DOI: 10.1111/j.1523-5378.2012.00936.x]
- 37 **Åberg A**, Gideonsson P, Vallström A, Olofsson A, Öhman C, Rakhimova L, Borén T, Engstrand L, Brännström K, Arnqvist A. A repetitive DNA element regulates expression of the *Helicobacter pylori* sialic acid binding adhesin by a rheostat-like mechanism. *PLoS Pathog* 2014; **10**: e1004234 [PMID: 24991812 DOI: 10.1371/journal.ppat.1004234]
- 38 **Zhou K**, Aertsen A, Michiels CW. The role of variable DNA tandem repeats in bacterial adaptation. *FEMS Microbiol Rev* 2014; **38**: 119-141 [PMID: 23927439 DOI: 10.1111/1574-6976.12036]
- 39 **Styer CM**, Hansen LM, Cooke CL, Gundersen AM, Choi SS, Berg DE, Benghezal M, Marshall BJ, Peek RM, Borén T, Solnick JV. Expression of the BabA adhesin during experimental infection with *Helicobacter pylori*. *Infect Immun* 2010; **78**: 1593-1600 [PMID: 20123715 DOI: 10.1128/IAI.01297-09]
- 40 **Nell S**, Kennemann L, Schwarz S, Josenhans C, Suerbaum S. Dynamics of Lewis b binding and sequence variation of the babA adhesin gene during chronic *Helicobacter pylori* infection in humans. *MBio* 2014; **5**: pii: e02281-14 [PMID: 25516619 DOI: 10.1128/mBio.02281-14]
- 41 **Gerhard M**, Lehn N, Neumayer N, Borén T, Rad R, Schepp W, Miehke S, Classen M, Prinz C. Clinical relevance of the *Helicobacter pylori* gene for blood-group antigen-binding adhesin. *Proc Natl Acad Sci USA* 1999; **96**: 12778-12783 [PMID: 10535999 DOI: 10.1073/pnas.96.22.12778]
- 42 **Saberi S**, Schmidt A, Eybpoosh S, Esmaili M, Talebkhani Y, Mohajerani N, Oghalaie A, Eshagh Hosseini M, Mohagheghi MA, Bugaytova J, Borén T, Mohammadi M. *Helicobacter pylori* Strains from Duodenal Ulcer Patients Exhibit Mixed babA/B Genotypes with Low Levels of BabA Adhesin and Lewis b Binding. *Dig Dis Sci* 2016; **61**: 2868-2877 [PMID: 27318698 DOI: 10.1007/s10620-016-4217-z]
- 43 **Abdullah SM**, Hussein NR, Salih AM, Merza MA, Goreal AA, Odeesh OY, Majed HS, Assafi MA, Hawrami K. Infection with *Helicobacter pylori* strains carrying babA2 and cagA is associated with an increased risk of peptic ulcer disease development in Iraq. *Arab J Gastroenterol* 2012; **13**: 166-169 [PMID: 23432983 DOI: 10.1016/j.ajg.2012.12.001]
- 44 **Karabiber H**, Selimoglu MA, Otlu B, Yildirim O, Ozer A. Virulence factors and antibiotic resistance in children with *Helicobacter pylori* gastritis. *J Pediatr Gastroenterol Nutr* 2014; **58**: 608-612 [PMID: 24792628 DOI: 10.1097/MPG.0000000000000273]
- 45 **Talebi Bezin Abadi A**, Taghvaei T, Mohabbati Mobarez A, Vaira G, Vaira D. High correlation of babA 2-positive strains of *Helicobacter pylori* with the presence of gastric cancer. *Intern Emerg Med* 2013; **8**: 497-501 [PMID: 21604199 DOI: 10.1007/s11739-011-0631-6]
- 46 **Yadegar A**, Mobarez AM, Alebouyeh M, Mirzaei T, Kwok T, Zali MR. Clinical relevance of cagL gene and virulence genotypes with disease outcomes in a *Helicobacter pylori* infected population from Iran. *World J Microbiol Biotechnol* 2014; **30**: 2481-2490 [PMID: 24854336 DOI: 10.1007/s11274-014-1673-5]
- 47 **Osman HA**, Hasan H, Suppian R, Hassan S, Andee DZ, Abdul Majid N, Zilfalil BA. Prevalence of *Helicobacter pylori* cagA, babA2, and dupA genotypes and correlation with clinical outcome in Malaysian patients with dyspepsia. *Turk J Med Sci* 2015; **45**: 940-946 [PMID: 26422871 DOI: 10.3906/sag-1409-77]
- 48 **Boonyanugomol W**, Chomvarin C, Sripa B, Chau-In S, Pughem A, Namwat W, Wongboot W, Khampoosa B. Molecular analysis of *Helicobacter pylori* virulent-associated genes in hepatobiliary patients. *HPB (Oxford)* 2012; **14**: 754-763 [PMID: 23043664 DOI: 10.1111/j.1477-2574.2012.00533.x]
- 49 **Chomvarin C**, Namwat W, Chaicumpar K, Mairiang P, Sangchan A, Sripa B, Tor-Udom S, Vilaichone RK. Prevalence of *Helicobacter pylori* vacA, cagA, cagE, iceA and babA2 genotypes in Thai dyspeptic patients. *Int J Infect Dis* 2008; **12**: 30-36 [PMID: 17548220 DOI: 10.1016/j.ijid.2007.03.012]
- 50 **Ghosh P**, Sarkar A, Ganguly M, Raghwan J, De R, Mukhopadhyay AK. *Helicobacter pylori* strains harboring babA2 from Indian sub population are associated with increased virulence in ex vivo study. *Gut Pathog* 2016; **8**: 1 [PMID: 26759607 DOI: 10.1186/s13099-015-0083-z]
- 51 **Con SA**, Takeuchi H, Nishioka M, Morimoto N, Sugiura T, Yasuda N, Con-Wong R. Clinical relevance of *Helicobacter pylori* babA2 and babA2/B in Costa Rica and Japan. *World J Gastroenterol* 2010; **16**: 474-478 [PMID: 20101774 DOI: 10.3748/wjg.v16.i4.474]
- 52 **Fujimoto S**, Olaniyi Ojo O, Arnqvist A, Wu JY, Odenbreit S, Haas R, Graham DY, Yamaoka Y. *Helicobacter pylori* BabA expression, gastric mucosal injury, and clinical outcome. *Clin Gastroenterol Hepatol* 2007; **5**: 49-58 [PMID: 17157077 DOI: 10.1016/j.cgh.2006.09.015]
- 53 **Biernat MM**, Gościński G, Iwańczak B. Prevalence of

- Helicobacter pylori cagA, vacA, iceA, babA2 genotypes in Polish children and adolescents with gastroduodenal disease. *Postepy Hig Med Dosw* (Online) 2014; **68**: 1015-1021 [PMID: 25228509 DOI: 10.5604/17322693.1118211]
- 54 **Homan M**, Šterbenc A, Kocjan BJ, Luzar B, Zidar N, Orel R, Poljak M. Prevalence of the Helicobacter pylori babA2 gene and correlation with the degree of gastritis in infected Slovenian children. *Antonie Van Leeuwenhoek* 2014; **106**: 637-645 [PMID: 25055876 DOI: 10.1007/s10482-014-0234-0]
- 55 **Boyanova L**, Yordanov D, Gergova G, Markovska R, Mitov I. Association of iceA and babA genotypes in Helicobacter pylori strains with patient and strain characteristics. *Antonie Van Leeuwenhoek* 2010; **98**: 343-350 [PMID: 20454856 DOI: 10.1007/s10482-010-9448-y]
- 56 **Odenbreit S**. Adherence properties of Helicobacter pylori: impact on pathogenesis and adaptation to the host. *Int J Med Microbiol* 2005; **295**: 317-324 [PMID: 16173498 DOI: 10.1016/j.ijmm.2005.06.003]
- 57 **Rhen M**, Eriksson S, Clements M, Bergström S, Normark SJ. The basis of persistent bacterial infections. *Trends Microbiol* 2003; **11**: 80-86 [PMID: 12598130 DOI: 10.1016/S0966-842X(02)00038-0]
- 58 **Aspholm M**, Kalia A, Ruhl S, Schedin S, Arnqvist A, Lindén S, Sjöström R, Gerhard M, Semino-Mora C, Dubois A, Unemo M, Danielsson D, Teneberg S, Lee WK, Berg DE, Borén T. Helicobacter pylori adhesion to carbohydrates. *Methods Enzymol* 2006; **417**: 293-339 [PMID: 17132512 DOI: 10.1016/S0076-6879(06)17020-2]
- 59 **Walz A**, Odenbreit S, Stühler K, Wattenberg A, Meyer HE, Mahdavi J, Borén T, Ruhl S. Identification of glycoprotein receptors within the human salivary proteome for the lectin-like BabA and SabA adhesins of Helicobacter pylori by fluorescence-based 2-D bacterial overlay. *Proteomics* 2009; **9**: 1582-1592 [PMID: 19253298 DOI: 10.1002/pmic.200700808]
- 60 **Prakobphol A**, Borén T, Ma W, Zhixiang P, Fisher SJ. Highly glycosylated human salivary molecules present oligosaccharides that mediate adhesion of leukocytes and Helicobacter pylori. *Biochemistry* 2005; **44**: 2216-2224 [PMID: 15697247 DOI: 10.1021/bi0480180]
- 61 **Prakobphol A**, Xu F, Hoang VM, Larsson T, Bergstrom J, Johansson I, Frängsmyr L, Holmskov U, Leffler H, Nilsson C, Borén T, Wright JR, Strömberg N, Fisher SJ. Salivary agglutinin, which binds Streptococcus mutans and Helicobacter pylori, is the lung scavenger receptor cysteine-rich protein gp-340. *J Biol Chem* 2000; **275**: 39860-39866 [PMID: 11007786 DOI: 10.1074/jbc.M006928200]
- 62 **Royle L**, Roos A, Harvey DJ, Wormald MR, van Gijlswijk-Janssen D, Redwan el-RM, Wilson IA, Daha MR, Dwek RA, Rudd PM. Secretory IgA N- and O-glycans provide a link between the innate and adaptive immune systems. *J Biol Chem* 2003; **278**: 20140-20153 [PMID: 12637583 DOI: 10.1074/jbc.M301436200]
- 63 **Issa S**, Moran AP, Ustinov SN, Lin JH, Ligtenberg AJ, Karlsson NG. O-linked oligosaccharides from salivary agglutinin: Helicobacter pylori binding sialyl-Lewis x and Lewis b are terminating moieties on hyperfucosylated oligo-N-acetyllactosamine. *Glycobiology* 2010; **20**: 1046-1057 [PMID: 20466654 DOI: 10.1093/glycob/cwq066]
- 64 **McGuckin MA**, Lindén SK, Sutton P, Florin TH. Mucin dynamics and enteric pathogens. *Nat Rev Microbiol* 2011; **9**: 265-278 [PMID: 21407243 DOI: 10.1038/nrmicro2538]
- 65 **Aspholm-Hurtig M**, Dailide G, Lahmann M, Kalia A, Ilver D, Roche N, Vikström S, Sjöström R, Lindén S, Bäckström A, Lundberg C, Arnqvist A, Mahdavi J, Nilsson UJ, Velapatiño B, Gilman RH, Gerhard M, Alarcon T, López-Brea M, Nakazawa T, Fox JG, Correa P, Dominguez-Bello MG, Perez-Perez GI, Blaser MJ, Normark S, Carlstedt I, Oscarson S, Teneberg S, Berg DE, Borén T. Functional adaptation of BabA, the H. pylori ABO blood group antigen binding adhesin. *Science* 2004; **305**: 519-522 [PMID: 15273394 DOI: 10.1126/science.1098801]
- 66 **Hage N**, Howard T, Phillips C, Brassington C, Overman R, Debreczeni J, Gellert P, Stolnik S, Winkler GS, Falcone FH. Structural basis of Lewis(b) antigen binding by the Helicobacter pylori adhesin BabA. *Sci Adv* 2015; **1**: e1500315 [PMID: 26601230 DOI: 10.1126/sciadv.1500315]
- 67 **Sakamoto S**, Watanabe T, Tokumaru T, Takagi H, Nakazato H, Lloyd KO. Expression of Lewis<sub>a</sub>, Lewis<sub>b</sub>, Lewis<sub>x</sub>, Lewis<sub>y</sub>, sialyl-Lewis<sub>a</sub>, and sialyl-Lewis<sub>x</sub> blood group antigens in human gastric carcinoma and in normal gastric tissue. *Cancer Res* 1989; **49**: 745-752 [PMID: 2910493]
- 68 **Lindén S**, Mahdavi J, Hedenbro J, Borén T, Carlstedt I. Effects of pH on Helicobacter pylori binding to human gastric mucins: identification of binding to non-MUC5AC mucins. *Biochem J* 2004; **384**: 263-270 [PMID: 15260802 DOI: 10.1042/BJ20040402]
- 69 **Kenny DT**, Skoog EC, Lindén SK, Struwe WB, Rudd PM, Karlsson NG. Presence of terminal N-acetylgalactosamineβ1-4N-acetylglucosamine residues on O-linked oligosaccharides from gastric MUC5AC: involvement in Helicobacter pylori colonization? *Glycobiology* 2012; **22**: 1077-1085 [PMID: 22543025 DOI: 10.1093/glycob/cws076]
- 70 **Magalhães A**, Rossez Y, Robbe-Masselot C, Maes E, Gomes J, Shevtsova A, Bugaytsova J, Borén T, Reis CA. Muc5ac gastric mucin glycosylation is shaped by FUT2 activity and functionally impacts Helicobacter pylori binding. *Sci Rep* 2016; **6**: 25575 [PMID: 27161092 DOI: 10.1038/srep25575]
- 71 **Lindén SK**, Sheng YH, Every AL, Miles KM, Skoog EC, Florin TH, Sutton P, McGuckin MA. MUC1 limits Helicobacter pylori infection both by steric hindrance and by acting as a releasable decoy. *PLoS Pathog* 2009; **5**: e1000617 [PMID: 19816567 DOI: 10.1371/journal.ppat.1000617]
- 72 **Cohen M**, Drut R, Cueto Rúa E. SIALYL-Tn antigen distribution in Helicobacter pylori chronic gastritis in children: an immunohistochemical study. *Pediatr Pathol Mol Med* 2003; **22**: 117-129 [PMID: 12556292 DOI: 10.1080/pdp.22.2.117.129]
- 73 **Lindén S**, Semino-Mora C, Liu H, Rick J, Dubois A. Role of mucin Lewis status in resistance to Helicobacter pylori infection in pediatric patients. *Helicobacter* 2010; **15**: 251-258 [PMID: 20633185 DOI: 10.1111/j.1523-5378.2010.00765.x]
- 74 **Lindén S**, Mahdavi J, Semino-Mora C, Olsen C, Carlstedt I, Borén T, Dubois A. Role of ABO secretor status in mucosal innate immunity and H. pylori infection. *PLoS Pathog* 2008; **4**: e2 [PMID: 18179282 DOI: 10.1371/journal.ppat.0040002]
- 75 **Moonens K**, Gideonsson P, Subedi S, Bugaytsova J, Romaõ E, Mendez M, Nordén J, Fallah M, Rakhimova L, Shevtsova A, Lahmann M, Castaldo G, Brännström K, Coppens F, Lo AW, Ny T, Solnick JV, Vandenbussche G, Oscarson S, Hammarström L, Arnqvist A, Berg DE, Muyltermans S, Borén T, Remaut H. Structural Insights into Polymorphic ABO Glycan Binding by Helicobacter pylori. *Cell Host Microbe* 2016; **19**: 55-66 [PMID: 26764597 DOI: 10.1016/j.chom.2015.12.004]
- 76 **Van de Bovenkamp JH**, Mahdavi J, Korteland-Van Male AM, Büller HA, Einerhand AW, Borén T, Dekker J. The MUC5AC glycoprotein is the primary receptor for Helicobacter pylori in the human stomach. *Helicobacter* 2003; **8**: 521-532 [PMID: 14535999 DOI: 10.1046/j.1523-5378.2003.00173.x]
- 77 **Suerbaum S**, Josenhans C. Helicobacter pylori evolution and phenotypic diversification in a changing host. *Nat Rev Microbiol* 2007; **5**: 441-452 [PMID: 17505524 DOI: 10.1038/nrmicro1658]
- 78 **Borst P**, Greaves DR. Programmed gene rearrangements altering gene expression. *Science* 1987; **235**: 658-667 [PMID: 3544215 DOI: 10.1126/science.3544215]
- 79 **Dworkin J**, Blaser MJ. Molecular mechanisms of Campylobacter fetus surface layer protein expression. *Mol Microbiol* 1997; **26**: 433-440 [PMID: 9402015 DOI: 10.1046/j.1365-2958.1997.6151958.x]
- 80 **Suerbaum S**, Smith JM, Bapumia K, Morelli G, Smith NH, Kunstmann E, Dyrek I, Achtman M. Free recombination within Helicobacter pylori. *Proc Natl Acad Sci USA* 1998; **95**: 12619-12624 [PMID: 9770535 DOI: 10.1073/pnas.95.21.12619]
- 81 **Loughlin MF**, Barnard FM, Jenkins D, Sharples GJ, Jenks PJ. Helicobacter pylori mutants defective in RuvC Holliday junction resolvase display reduced macrophage survival and

- spontaneous clearance from the murine gastric mucosa. *Infect Immun* 2003; **71**: 2022-2031 [PMID: 12654822 DOI: 10.1128/IAI.71.4.2022-2031.2003]
- 82 **Kennemann L**, Didelot X, Aebischer T, Kuhn S, Drescher B, Droege M, Reinhardt R, Correa P, Meyer TF, Josenhans C, Falush D, Suerbaum S. Helicobacter pylori genome evolution during human infection. *Proc Natl Acad Sci USA* 2011; **108**: 5033-5038 [PMID: 21383187 DOI: 10.1073/pnas.1018444108]
- 83 **Yahara K**, Kawai M, Furuta Y, Takahashi N, Handa N, Tsuru T, Oshima K, Yoshida M, Azuma T, Hattori M, Uchiyama I, Kobayashi I. Genome-wide survey of mutual homologous recombination in a highly sexual bacterial species. *Genome Biol Evol* 2012; **4**: 628-640 [PMID: 22534164 DOI: 10.1093/gbe/evs043]
- 84 **Solnick JV**, Hansen LM, Salama NR, Boonjakuakul JK, Syvanen M. Modification of Helicobacter pylori outer membrane protein expression during experimental infection of rhesus macaques. *Proc Natl Acad Sci USA* 2004; **101**: 2106-2111 [PMID: 14762173 DOI: 10.1073/pnas.0308573100]
- 85 **Field D**, Wills C. Abundant microsatellite polymorphism in Saccharomyces cerevisiae, and the different distributions of microsatellites in eight prokaryotes and S. cerevisiae, result from strong mutation pressures and a variety of selective forces. *Proc Natl Acad Sci USA* 1998; **95**: 1647-1652 [PMID: 9465070]
- 86 **van Belkum A**, Scherer S, van Alphen L, Verbrugh H. Short-sequence DNA repeats in prokaryotic genomes. *Microbiol Mol Biol Rev* 1998; **62**: 275-293 [PMID: 9618442]
- 87 **Henderson IR**, Owen P, Nataro JP. Molecular switches--the ON and OFF of bacterial phase variation. *Mol Microbiol* 1999; **33**: 919-932 [PMID: 10476027 DOI: 10.1046/j.1365-2958.1999.01555.x]
- 88 **Levinson G**, Gutman GA. Slipped-strand mispairing: a major mechanism for DNA sequence evolution. *Mol Biol Evol* 1987; **4**: 203-221 [PMID: 3328815]
- 89 **Kennemann L**, Brenneke B, Andres S, Engstrand L, Meyer TF, Aebischer T, Josenhans C, Suerbaum S. In vivo sequence variation in HopZ, a phase-variable outer membrane protein of Helicobacter pylori. *Infect Immun* 2012; **80**: 4364-4373 [PMID: 23027539 DOI: 10.1128/IAI.00977-12]
- 90 **Zhang J**, Qian J, Zhang X, Zou Q. Outer membrane inflammatory protein A, a new virulence factor involved in the pathogenesis of Helicobacter pylori. *Mol Biol Rep* 2014; **41**: 7807-7814 [PMID: 25096514 DOI: 10.1007/s11033-014-3673-9]
- 91 **Myers P**. Tandem repeats and morphological variation. *Nature Education* 2007; **1**: 1 Available from URL: <http://www.nature.com/scitable/topicpage/tandem-repeats-and-morphological-variation-40690>
- 92 **de Vries N**, Duinsbergen D, Kuipers EJ, Pot RG, Wiesenecker P, Penn CW, van Vliet AH, Vandenbroucke-Grauls CM, Kusters JG. Transcriptional phase variation of a type III restriction-modification system in Helicobacter pylori. *J Bacteriol* 2002; **184**: 6615-6623 [PMID: 12426350 DOI: 10.1128/JB.184.23.6615-6624.2002]
- 93 **van der Woude MW**, Bäumlér AJ. Phase and antigenic variation in bacteria. *Clin Microbiol Rev* 2004; **17**: 581-611, table of contents [PMID: 15258095 DOI: 10.1128/CMR.17.3.581-611.2004]
- 94 **Toller IM**, Neelsen KJ, Steger M, Hartung ML, Hottiger MO, Stucki M, Kalali B, Gerhard M, Sartori AA, Lopes M, Müller A. Carcinogenic bacterial pathogen Helicobacter pylori triggers DNA double-strand breaks and a DNA damage response in its host cells. *Proc Natl Acad Sci USA* 2011; **108**: 14944-14949 [PMID: 21896770 DOI: 10.1073/pnas.1100959108]
- 95 **Azevedo M**, Eriksson S, Mendes N, Serpa J, Figueiredo C, Resende LP, Ruvoën-Clouet N, Haas R, Borén T, Le Pendu J, David L. Infection by Helicobacter pylori expressing the BabA adhesin is influenced by the secretor phenotype. *J Pathol* 2008; **215**: 308-316 [PMID: 18498114 DOI: 10.1002/path.2363]
- 96 **Olfat FO**, Zheng Q, Oleastro M, Voland P, Borén T, Karttunen R, Engstrand L, Rad R, Prinz C, Gerhard M. Correlation of the Helicobacter pylori adherence factor BabA with duodenal ulcer disease in four European countries. *FEMS Immunol Med Microbiol* 2005; **44**: 151-156 [PMID: 15866209 DOI: 10.1016/j.femsim.2004.10.010]
- 97 **Sheu BS**, Sheu SM, Yang HB, Huang AH, Wu JJ. Host gastric Lewis expression determines the bacterial density of Helicobacter pylori in babA2 genopositive infection. *Gut* 2003; **52**: 927-932 [PMID: 12801945 DOI: 10.1136/gut.52.7.927]
- 98 **Mizushima T**, Sugiyama T, Komatsu Y, Ishizuka J, Kato M, Asaka M. Clinical relevance of the babA2 genotype of Helicobacter pylori in Japanese clinical isolates. *J Clin Microbiol* 2001; **39**: 2463-2465 [PMID: 11427555 DOI: 10.1128/JCM.39.7.2463-2465.2001]
- 99 **Oleastro M**, Cordeiro R, Yamaoka Y, Queiroz D, Mégraud F, Monteiro L, Ménard A. Disease association with two Helicobacter pylori duplicate outer membrane protein genes, homB and homA. *Gut Pathog* 2009; **1**: 12 [PMID: 19545429 DOI: 10.1186/1757-4749-1-12]
- 100 **Ishijima N**, Suzuki M, Ashida H, Ichikawa Y, Kanegae Y, Saito I, Borén T, Haas R, Sasakawa C, Mimuro H. BabA-mediated adherence is a potentiator of the Helicobacter pylori type IV secretion system activity. *J Biol Chem* 2011; **286**: 25256-25264 [PMID: 21596743 DOI: 10.1074/jbc.M111.233601]
- 101 **Rad R**, Gerhard M, Lang R, Schöniger M, Rösch T, Schepp W, Becker I, Wagner H, Prinz C. The Helicobacter pylori blood group antigen-binding adhesin facilitates bacterial colonization and augments a nonspecific immune response. *J Immunol* 2002; **168**: 3033-3041 [PMID: 11884476 DOI: 10.4049/jimmunol.168.6.3033]

**P- Reviewer:** Kuo FC, Safaei HG, Yamaoka Y **S- Editor:** Qi Y

**L- Editor:** A **E- Editor:** Zhang FF





Published by **Baishideng Publishing Group Inc**  
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA  
Telephone: +1-925-223-8242  
Fax: +1-925-223-8243  
E-mail: [bpgooffice@wjgnet.com](mailto:bpgooffice@wjgnet.com)  
Help Desk: <http://www.f6publishing.com/helpdesk>  
<http://www.wjgnet.com>



ISSN 1007-9327



9 771007 932045